amikacin has been researched along with azomycin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C | 1 |
| Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P | 1 |
| Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
| Nambiar, S; Schumann, K; Walinsky, S | 1 |
1 review(s) available for amikacin and azomycin
| Article | Year |
|---|---|
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
3 other study(ies) available for amikacin and azomycin
| Article | Year |
|---|---|
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors | 2006 |
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin | 2018 |
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration | 2021 |